Clinical Trial: SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy

U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07524374) titled 'SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy' on March 25.

Brief Summary: This study is a single-arm, exploratory clinical trial aimed at evaluating the efficacy and safety of SHR-1701 in combination with liposomal irinotecan (II) in patients with esophageal squamous cell carcinoma who have received prior immunotherapy. Eligible patients with esophageal cancer will be treated with SHR-1701 in combination with liposomal irinotecan (II).

Study Start Date: March 15

Study Type: INTERVENTIONAL

Condition: ESCC

Intervention: DRUG: SHR-1701+ liposomal irinotecan (II)

SHR...